About Us

Wockhardt USA encourages you to carefully read and review this Privacy Policy Statement before accessing or using this website. If you proceed to access or use this website, you are agreeing to abide by this Privacy Policy Statement, without any limitations. You may not access or use this website if you do not agree to this Privacy Policy Statement. Wockhardt USA and its affiliate companies (hereinafter referred to as “Wockhardt”) reserve the right to add, remove or modify this information at any time without any prior notification.

1. The Wockhardt website is not designed to collect and/or receive any personally identifiable information. Wockhardt is not able to identify you personally unless you provide any personally identifiable information including but not limited to email address, telephone number, name and alike.

2. A visitor of Wockhardt website may provide personally identifiable information including but not limited to, the visitor’s name, address, phone number, email address or any other type of information that may identify a visitor. Wockhardt does not want you to provide personal or confidential health information. Wockhardt accepts any such personally identifiable information only when it is voluntarily provided.

3. Wockhardt may use any information provided information in order to plan its resource requirements and/or to assess the website usage and enhancement of the information herein.

4. The information you submit on this website may be transferred to other Wockhardt affiliates or subsidiaries throughout the world. Wockhardt may provide any submitted information to the required entities in the event of a court order or a government stipulation.

5. Any information received from user of this website including but not limited to, comments, questions, feedback, data, suggestions, ideas and alike is and will be deemed non-confidential. Wockhardt shall have no obligation of any kind with respect to such information and shall be free to use, reproduce, disclose and/or redistribute to others without limitation or use such information, including but not limited to ideas, concepts, know-how for the purpose of, including but not limited to, manufacturing, developing, marketing and/or advertising any products incorporating such information, either partly or wholly.

USA History

usa history

"Wockhardt has a strong track record of acquisition management, forming strategic alliances and developing a world-class organization and culture."

Wockhardt Limited created its US subsidiary Wockhardt USA in early 2004 with a modest portfolio of three FDA—approved generic products. Today, Wockhardt USA LLC is a leader in providing high-quality line of generic oral solids, liquids, topicals, and injectables in the United States. We have been producing and distributing quality products in the United States for more than 13 years and have received over 110 ANDA approvals to date.

Chicago-based Morton Grove Pharmaceuticals was acquired by Wockhardt Limited in October 2007 in order to expand Wockhardt's product line in the US. Since 1995. Morton Grove has been a leading manufacturer and marketer of oral liquid and topical pharmaceuticals. The company's core products are manufactured in its 125,000 square foot, state-of-the-art facility.

Corporate Information


As a global, research-based pharmaceutical and biotechnology company, we have come a long way. Wockhardt today is an Indian MNC with a multi-ethnic global workforce spanning 27 nationalities; 11 manufacturing facilities across India, the US and Europe; and 3 cutting-edge R&D facilities in India, UK and US.

To maintain our edge in a field that is as highly competitive as it is closely regulated, we have to constantly reinvent ourselves by focusing and building on core values and intrinsic strengths.

The measure of any organisation is the quality of its leadership. At Wockhardt, we have taken significant steps to strengthen leadership and improve and enhance organisational development. The new leadership team in place has brought about visible change that has resulted in an organisational turnaround that has led to improved product availability, better quality and true value addition.

The compliances pertaining to US FDA have our full attention and we are in the process of addressing them to a positive outcome.

Congratulations are in order for Team Wockhardt as it continued with its winning streak of winning several awards for excellence this year too. Finally, the tremendous achievement of Wockhardt's R&D team cannot be highlighted enough. Thanks to their long and focused endeavour in New Drug Discovery in antibiotics, Wockhardt today is the only pharmaceutical company in the world to have 5 NCEs with QIDP status from US FDA that are in Phase II & Phase III clinical trials. A milestone achievement indeed in a milestone year for Wockhardt!

Visit our corporate website for more information

Management Team

quote icon

"An experienced leadership team of industry professionals committed to serving the US healthcare marketplace with high-quality products and innovative treatment solutions and education."